NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.010
-0.002 (-0.20%)
Jul 24, 2026, 4:58 PM CET
NextCell Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Dec '24 Dec 31, 2024 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 |
| 10.61 | 13.96 | 11.06 | 11.28 | 11.28 | 13.96 | |
Revenue Growth (YoY) | 0.59% | 26.17% | -1.90% | - | -19.18% | 124.03% |
Cost of Revenue | 7.73 | 11.77 | 9.4 | 15.22 | 15.22 | 11 |
Gross Profit | 2.89 | 2.19 | 1.67 | -3.94 | -3.94 | 2.96 |
Selling, General & Admin | 40.76 | 50.64 | 34.9 | 38.22 | 38.22 | 43.47 |
Depreciation & Amortization Expenses | 2.49 | 3.36 | 2.52 | 0.97 | 0.97 | 0.45 |
Other Operating Expenses | -0.22 | 0.02 | 0.14 | 0.04 | 0.04 | 0.04 |
Total Operating Expenses | 43.03 | 54.01 | 37.55 | 39.23 | 39.23 | 43.96 |
Operating Income | -40.14 | -51.82 | -35.89 | -43.17 | -43.17 | -41 |
Interest Income | 0.52 | 0.89 | 0.75 | 1.21 | 1.21 | 1.19 |
Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 |
Total Non-Operating Income (Expense) | 0.52 | 0.89 | 0.74 | 1.21 | 1.21 | 1.19 |
Pretax Income | -39.62 | -50.93 | -35.14 | -41.96 | -41.96 | -39.81 |
Net Income | -39.62 | -50.93 | -35.14 | -41.96 | -41.96 | -39.81 |
Net Income to Common | -39.62 | -50.93 | -35.14 | -41.96 | -41.96 | -39.81 |
Shares Outstanding (Basic) | 106 | 85 | 76 | 41 | 41 | 34 |
Shares Outstanding (Diluted) | 106 | 85 | 76 | 41 | 41 | 34 |
Shares Change (YoY) | -4.55% | 11.67% | 87.38% | -0.09% | 18.72% | - |
EPS (Basic) | -0.37 | -0.60 | -0.46 | -1.06 | -1.03 | -1.16 |
EPS (Diluted) | -0.37 | -0.60 | -0.46 | -1.06 | -1.03 | -1.16 |
Free Cash Flow | -41.83 | -55.87 | -39.28 | -39.6 | -37.86 | -47.92 |
Free Cash Flow Per Share | -0.39 | -0.65 | -0.51 | -0.97 | -0.93 | -1.39 |
Gross Margin | 27.19% | 15.70% | 15.07% | -34.97% | -34.97% | 21.19% |
Operating Margin | -378.20% | -371.21% | -324.35% | -382.79% | -382.79% | -293.81% |
Profit Margin | -373.34% | -364.85% | -317.62% | -372.04% | -372.04% | -285.28% |
FCF Margin | -394.08% | -400.18% | -355.03% | -351.10% | -335.70% | -343.41% |
EBITDA | -38.27 | -48.46 | -33.37 | -42.74 | -42.2 | -40.55 |
EBITDA Margin | -360.59% | -347.16% | -301.62% | -378.97% | -374.15% | -290.60% |
EBIT | -40.14 | -51.82 | -35.89 | -43.17 | -43.17 | -41 |
EBIT Margin | -378.20% | -371.21% | -324.35% | -382.79% | -382.79% | -293.81% |